|
1
|
Gibbons RJ, Picketts DJ, Villard L and
Higgs DR: Mutations in a putative global transcriptional regulator
cause X-linked mental retardation with alpha-thalassemia (ATR-X
syndrome). Cell. 80:837–845. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villard L and Fontes M:
Alpha-thalassemia/mental retardation syndrome, X-Linked (ATR-X, MIM
#301040, ATR-X/XNP/XH2 gene MIM #300032). Eur J Hum Genet.
10:223–225. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qadeer ZA, Harcharik S, Valle-Garcia D,
Chen C, Birge MB, Vardabasso C, Duarte LF and Bernstein E:
Decreased expression of the chromatin remodeler ATRX associates
with melanoma progression. J Invest Dermatol. 134:1768–1772. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cai J, Chen J, Zhang W, Yang P, Zhang C,
Li M, Yao K, Wang H, Li Q, Jiang C and Jiang T: Loss of ATRX,
associated with DNA methylation pattern of chromosome end, impacted
biological behaviors of astrocytic tumors. Oncotarget.
6:18105–18115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gibbons RJ and Higgs DR:
Molecular-clinical spectrum of the ATR-X syndrome. Am J Med Genet.
97:204–212. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cardoso C, Timsit S, Villard L,
Khrestchatisky M, Fontès M and Colleaux L: Specific interaction
between the XNP/ATR-X gene product and the SET domain of the human
EZH2 protein. Hum Mol Genet. 7:679–684. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reimann E, Kõks S, Ho XD, Maasalu K and
Märtson A: Whole exome sequencing of a single osteosarcoma
case-integrative analysis with whole transcriptome RNA-seq data.
Hum Genomics. 8:202014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bousquet M, Noirot C, Accadbled F, de
Gauzy Sales J, Castex MP, Brousset P and Gomez-Brouchet A:
Whole-exome sequencing in osteosarcoma reveals important
heterogeneity of genetic alterations. Ann Oncol. 27:738–744. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde
I, Wu J, Mandahl N, Luo J, Hruban RH, Diaz LA Jr, et al: Exomic
analysis of myxoid liposarcomas, synovial sarcomas, and
osteosarcomas. Genes Chromosomes Cancer. 53:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Yuan Q and Wang W: The role of
telomeres in musculoskeletal diseases. J Int Med Res. 40:1242–1250.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozturk MB, Li Y and Tergaonkar V: Current
insights to regulation and role of telomerase in human diseases.
Antioxidants (Basel). 6:pii: E17. 2017.PubMed/NCBI
|
|
13
|
Henderson ER and Blackburn EH: An
overhanging 3′ terminus is a conserved feature of telomeres. Mol
Cell Biol. 9:345–348. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayflick L and Moorhead PS: The serial
cultivation of human diploid cell strains. Exp Cell Res.
25:585–621. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shay JW: Role of telomeres and telomerase
in aging and cancer. Cancer Discov. 6:584–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Günes C and Rudolph KL: The role of
telomeres in stem cells and cancer. Cell. 152:390–393. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harley CB and Villeponteau B: Telomeres
and telomerase in aging and cancer. Curr Opin Genet Dev. 5:249–255.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Artandi SE and DePinho RA: Telomeres and
telomerase in cancer. Carcinogenesis. 31:9–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cesare AJ and Reddel RR: Alternative
lengthening of telomeres: Models, mechanisms and implications. Nat
Rev Genet. 11:319–330. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heaphy CM, Subhawong AP, Hong SM, Goggins
MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL,
Westra WH, et al: Prevalence of the alternative lengthening of
telomeres telomere maintenance mechanism in human cancer subtypes.
Am J Pathol. 179:1608–1615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sidaway P: Sarcoma: Genetic determinants
of sarcoma risk revealed. Nat Rev Clin Oncol. 13:5902016.
View Article : Google Scholar
|
|
22
|
Thomas DM and Ballinger ML: Diagnosis and
management of hereditary sarcoma. Recent Results Cancer Res.
205:169–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ballinger ML, Goode DL, Ray-Coquard I,
James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS,
Cipponi A, et al: Monogenic and polygenic determinants of sarcoma
risk: An international genetic study. Lancet Oncol. 17:1261–1271.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Antonescu CR: The role of genetic testing
in soft tissue sarcoma. Histopathology. 48:13–21. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bridge JA: The role of cytogenetics and
molecular diagnostics in the diagnosis of soft-tissue tumors. Mod
Pathol. 27 Suppl 1:S80–S97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rosenberg AE: WHO classification of soft
tissue and bone, fourth edition: Summary and commentary. Curr Opin
Oncol. 25:571–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zambo I and Veselý K: WHO classification
of tumours of soft tissue and bone 2013: The main changes compared
to the 3rd edition. Cesk Patol. 50:64–70. 2014.PubMed/NCBI
|
|
28
|
Ji J, Quindipan C, Parham D, Shen L, Ruble
D, Bootwalla M, Maglinte DT, Gai X, Saitta SC, Biegel JA and
Mascarenhas L: Inherited germline ATRX mutation in two brothers
with ATR-X syndrome and osteosarcoma. Am J Med Genet A.
173:1390–1395. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smolle MA, Heitzer E, Geigl JB, Al Kaissi
A, Liegl-Atzwanger B, Seidel MG, Holzer LA and Leithner A: A novel
mutation in ATRX associated with intellectual disability, syndromic
features, and osteosarcoma. Pediatr Blood Cancer. 64:e265222017.
View Article : Google Scholar
|
|
30
|
Liau JY, Lee JC, Tsai JH, Yang CY, Liu TL,
Ke ZL, Hsu HH and Jeng YM: Comprehensive screening of alternative
lengthening of telomeres phenotype and loss of ATRX expression in
sarcomas. Mod Pathol. 28:1545–1554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kovac M, Blattmann C, Ribi S, Smida J,
Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M,
Krieg A, et al: Exome sequencing of osteosarcoma reveals mutation
signatures reminiscent of BRCA deficiency. Nat Commun. 6:89402015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH
and Yang CY: Leiomyosarcoma with alternative lengthening of
telomeres is associated with aggressive histologic features, loss
of ATRX expression, and poor clinical outcome. Am J Surg Pathol.
39:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee PJ, Yoo NS, Hagemann IS, Pfeifer JD,
Cottrell CE, Abel HJ and Duncavage EJ: Spectrum of mutations in
leiomyosarcomas identified by clinical targeted next-generation
sequencing. Exp Mol Pathol. 102:156–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mäkinen N, Aavikko M, Heikkinen T, Taipale
M, Taipale J, Koivisto-Korander R, Bützow R and Vahteristo P: Exome
sequencing of uterine leiomyosarcomas identifies frequent mutations
in TP53, ATRX, and MED12. PLoS Genet. 12:e10058502016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang CY, Liau JY, Huang WJ, Chang YT,
Chang MC, Lee JC, Tsai JH, Su YN, Hung CC and Jeng YM: Targeted
next-generation sequencing of cancer genes identified frequent TP53
and ATRX mutations in leiomyosarcoma. Am J Transl Res. 7:2072–2081.
2015.PubMed/NCBI
|
|
37
|
Hartmann C, Meyer J, Balss J, Capper D,
Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et
al: Type and frequency of IDH1 and IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: A study of
1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cleven AHG, Suijker J, Agrogiannis G,
Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM,
Cleton-Jansen AM and Bovée JVMG: IDH1 or −2 mutations do not
predict outcome and do not cause loss of 5-hydroxymethylcytosine or
altered histone modifications in central chondrosarcomas. Clin
Sarcoma Res. 7:82017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnson JE, Varkonyi RJ, Schwalm J, Cragle
R, Klein-Szanto A, Patchefsky A, Cukierman E, von Mehren M and
Broccoli D: Multiple mechanisms of telomere maintenance exist in
liposarcomas. Clin Cancer Res. 11:5347–5355. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JC, Jeng YM, Liau JY, Tsai JH, Hsu HH
and Yang CY: Alternative lengthening of telomeres and loss of ATRX
are frequent events in pleomorphic and dedifferentiated
liposarcomas. Mod Pathol. 28:1064–1073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Venturini L, Motta R, Gronchi A, Daidone M
and Zaffaroni N: Prognostic relevance of ALT-associated markers in
liposarcoma: A comparative analysis. BMC Cancer. 10:2542010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liau JY, Tsai JH, Yang CY, Lee JC, Liang
CW, Hsu HH and Jeng YM: Alternative lengthening of telomeres
phenotype in malignant vascular tumors is highly associated with
loss of ATRX expression and is frequently observed in hepatic
angiosarcomas. Hum Pathol. 46:1360–1366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Willems SM, Debiec-Rychter M, Szuhai K,
Hogendoorn PC and Sciot R: Local recurrence of myxofibrosarcoma is
associated with increase in tumour grade and cytogenetic
aberrations, suggesting a multistep tumour progression model. Mod
Pathol. 19:407–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hechtman JF, Zehir A, Mitchell T, Borsu L,
Singer S, Tap W, Oultache A, Ladanyi M and Nafa K: Novel oncogene
and tumor suppressor mutations in KIT and PDGFRA wild type
gastrointestinal stromal tumors revealed by next generation
sequencing. Genes Chromosomes Cancer. 54:177–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Napier CE, Huschtscha LI, Harvey A, Bower
K, Noble JR, Hendrickson EA and Reddel RR: ATRX represses
alternative lengthening of telomeres. Oncotarget. 6:16543–16558.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Flynn RL, Cox KE, Jeitany M, Wakimoto H,
Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, et al:
Alternative lengthening of telomeres renders cancer cells
hypersensitive to ATR inhibitors. Science. 347:273–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Deeg KI, Chung I, Bauer C and Rippe K:
Cancer cells with alternative lengthening of telomeres do not
display a general hypersensitivity to ATR inhibition. Front Oncol.
6:1862016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McFarlane S and Preston CM: Human
cytomegalovirus immediate early gene expression in the osteosarcoma
line U2OS is repressed by the cell protein ATRX. Virus Res.
157:47–53. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kovatcheva M, Liu DD, Dickson MA, Klein
ME, O'Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S,
et al: MDM2 turnover and expression of ATRX determine the choice
between quiescence and senescence in response to CDK4 inhibition.
Oncotarget. 6:8226–8243. 2015. View Article : Google Scholar : PubMed/NCBI
|
